trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Retatrutide is an experimental drug that activates the GIP, GLP-1, and glucagon receptors.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
7 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Retatrutide is an experimental drug that activates the GIP, GLP-1, and glucagon receptors?

Yes. Multiple independent peer-reviewed reviews and reference sources describe retatrutide as an experimental triple agonist acting at the GLP-1, GIP and glucagon receptors, matching the claim exactly. One review mentions only glucagon and GLP-1 activation, covering part of the receptor profile.

Verdict: SUPPORTED · 7 sources for, 0 against · Last checked

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Evidence for · 7
Retatrutide
Get citation
Retatrutide. (n.d.). en.wikipedia.org. https://en.wikipedia.org/wiki/Retatrutide

See more details
More for · 6
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
2025
Get citation
A, A. A., AM, A., MN, B., F, A., A, M., Y, T., DM, A., & MM, B. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.. doi.org. https://doi.org/10.1080/08998280.2025.2456441

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
2025
Get citation
B, S. & S, G. (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.. doi.org. https://doi.org/10.1002/oby.24360

Retatrutide—A Game Changer in Obesity Pharmacotherapy -
Get citation
Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMC Lock. (n.d.). pmc.ncbi.nlm.nih.gov. https://doi.org/10.3390/biom15060796

2 recorded entries grouped as this source

Additional records of the same source are shown below. They are not counted as additional sources.

Retatrutide-A Game Changer in Obesity Pharmacotherapy.
2025
Get citation
V, K., G, K., C, F., K, D., & K, T. (2025). Retatrutide-A Game Changer in Obesity Pharmacotherapy.. doi.org. https://doi.org/10.3390/biom15060796

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Get citation
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. (n.d.). cir.nii.ac.jp. https://doi.org/10.2337/dci24-0003

Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.
2026
Get citation
L, A., AG, L., I, L., D, M., A, I., DL, D., & F, L. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.. doi.org. https://doi.org/10.3390/medicina62050986

Type 2 Diabetes Mellitus
2026
Get citation
Bashir, H., Ali, S., & Jamous, Y. F. M. (2026). Type 2 Diabetes Mellitus. play.google.com. https://play.google.com/store/books/details?id=fKE7EQAAQBAJ&source=gbs_api

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work